Drug intelligence / Profile preview

oxycodone + risperidone

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Oxycodone + risperidone is an investigational combination of two FDA-approved drugs, oxycodone (an opioid analgesic) and risperidone (an atypical antipsychotic). Oxycodone acts primarily as a mu-type opioid receptor agonist to provide analgesia for moderate to severe pain. Risperidone is a dopamine D2 receptor antagonist used in the treatment of schizophrenia, bipolar disorder, and irritability associated with autism. The rationale for combining these agents is to maintain the analgesic efficacy of oxycodone while potentially reducing its abuse liability by blocking dopaminergic reward pathways via D2 antagonism. Early clinical studies indicate that this combination does not significantly alter the analgesic effect of oxycodone or increase adverse effects compared to oxycodone alone[1][5]. This approach may be beneficial in chronic pain management by mitigating opioid abuse potential.

02

Targets

HTR2A (Serotonin receptor 5-HT2A)MOR (Mu opioid receptor)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on oxycodone + risperidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxycodone + risperidone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call